Background: 25-30% of renal cell carcinoma presents with metastases (mRCC) at diagnosis. The activity of immune checkpoint inhibitor (ICI)-combinations on the primary tumor (PT) is debated. Patients andMethods: mRCC patients (pts) with PT who received first-line nivolumab plus ipilimumab (N/I) or pembrolizumab plus axitinib (P/A) were included. We investigated the early primary tumor response (EPTR) at the first radiological assessment. Results: 73 pts were included. The median early reduction of the PT longest diameter was 12.4% with P/A versus 6.2% with N/I (p = 0.42). We evaluated if the type of EPTR could affect the metastases response. Among pts with PT stable disease (SD), 8.3% had metastatic disease progression (PD) with P/A and 34.8% with N/I. Early PT partial response (PR) was associated with no metastatic PD with both N/I and P/A. The 2 pts with PT PD had also metastatic PD to P/A. Of the 3 PT with PD to N/I, 1 had metastatic SD and 2 PD. In the overall population, of the 94.1% without PT progression (PR+SD), 47.5% had metastatic PR, 35.6% SD, 16.9% PD. Conclusions: ICIs-combinations achieved an early PT PR in about 10-20%, without any complete responses. Only a small percentage of PT had an early PD, mainly associated with metastatic PD. However, among those PT without an early progression, metastatic PR can be achieved in approximately 50% of cases.

Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations / Ciccarese, Chiara; Bimbatti, Davide; Atzori, Francesco; Bonato, Adele; Scagliarini, Sarah; Pellegrini, Ilaria; Bracarda, Sergio; De Giorgi, Ugo; Masini, Cristina; Santoni, Matteo; Massari, Francesco; Buti, Sebastiano; Damassi, Alessandra; Zampiva, Ilaria; Strusi, Alessandro; Sparagna, Ileana; Rebuzzi, Sara Elena; Tortora, Giampaolo; Iacovelli, Roberto. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 40:6_suppl(2022), pp. 349-349. [10.1200/JCO.2022.40.6_suppl.349]

Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations

Buti, Sebastiano;
2022

Abstract

Background: 25-30% of renal cell carcinoma presents with metastases (mRCC) at diagnosis. The activity of immune checkpoint inhibitor (ICI)-combinations on the primary tumor (PT) is debated. Patients andMethods: mRCC patients (pts) with PT who received first-line nivolumab plus ipilimumab (N/I) or pembrolizumab plus axitinib (P/A) were included. We investigated the early primary tumor response (EPTR) at the first radiological assessment. Results: 73 pts were included. The median early reduction of the PT longest diameter was 12.4% with P/A versus 6.2% with N/I (p = 0.42). We evaluated if the type of EPTR could affect the metastases response. Among pts with PT stable disease (SD), 8.3% had metastatic disease progression (PD) with P/A and 34.8% with N/I. Early PT partial response (PR) was associated with no metastatic PD with both N/I and P/A. The 2 pts with PT PD had also metastatic PD to P/A. Of the 3 PT with PD to N/I, 1 had metastatic SD and 2 PD. In the overall population, of the 94.1% without PT progression (PR+SD), 47.5% had metastatic PR, 35.6% SD, 16.9% PD. Conclusions: ICIs-combinations achieved an early PT PR in about 10-20%, without any complete responses. Only a small percentage of PT had an early PD, mainly associated with metastatic PD. However, among those PT without an early progression, metastatic PR can be achieved in approximately 50% of cases.
Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations / Ciccarese, Chiara; Bimbatti, Davide; Atzori, Francesco; Bonato, Adele; Scagliarini, Sarah; Pellegrini, Ilaria; Bracarda, Sergio; De Giorgi, Ugo; Masini, Cristina; Santoni, Matteo; Massari, Francesco; Buti, Sebastiano; Damassi, Alessandra; Zampiva, Ilaria; Strusi, Alessandro; Sparagna, Ileana; Rebuzzi, Sara Elena; Tortora, Giampaolo; Iacovelli, Roberto. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 40:6_suppl(2022), pp. 349-349. [10.1200/JCO.2022.40.6_suppl.349]
File in questo prodotto:
File Dimensione Formato  
Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations. _ Journal of Clinical Oncology.pdf

accesso aperto

Tipologia: Abstract
Licenza: Creative commons
Dimensione 997.3 kB
Formato Adobe PDF
997.3 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2916230
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact